DK1121115T4 - PUFA-tilskud - Google Patents

PUFA-tilskud

Info

Publication number
DK1121115T4
DK1121115T4 DK99970319.2T DK99970319T DK1121115T4 DK 1121115 T4 DK1121115 T4 DK 1121115T4 DK 99970319 T DK99970319 T DK 99970319T DK 1121115 T4 DK1121115 T4 DK 1121115T4
Authority
DK
Denmark
Prior art keywords
ara
dha
pufas
pharmaceutical compositions
disclosed
Prior art date
Application number
DK99970319.2T
Other languages
English (en)
Other versions
DK1121115T3 (da
Inventor
Hugo Streekstra
Waterschoot Isabel Antonia Maria Van
Original Assignee
Dsm Ip Assets Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8235104&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1121115(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dsm Ip Assets Bv filed Critical Dsm Ip Assets Bv
Application granted granted Critical
Publication of DK1121115T3 publication Critical patent/DK1121115T3/da
Publication of DK1121115T4 publication Critical patent/DK1121115T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Polymers & Plastics (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Animal Husbandry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
DK99970319.2T 1998-10-15 1999-10-15 PUFA-tilskud DK1121115T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98308403 1998-10-15
PCT/EP1999/007834 WO2000021524A1 (en) 1998-10-15 1999-10-15 Pufa supplements

Publications (2)

Publication Number Publication Date
DK1121115T3 DK1121115T3 (da) 2007-07-02
DK1121115T4 true DK1121115T4 (da) 2011-01-10

Family

ID=8235104

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99970319.2T DK1121115T4 (da) 1998-10-15 1999-10-15 PUFA-tilskud

Country Status (13)

Country Link
US (2) US20070184090A1 (da)
EP (4) EP2292223A1 (da)
JP (2) JP2002527387A (da)
CN (3) CN1326344A (da)
AT (1) ATE361066T1 (da)
AU (2) AU775421B2 (da)
CA (2) CA2355341C (da)
DE (1) DE69935995T3 (da)
DK (1) DK1121115T4 (da)
ES (1) ES2284286T5 (da)
HK (1) HK1042441A1 (da)
NZ (1) NZ511071A (da)
WO (1) WO2000021524A1 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
PT1322752E (pt) 2000-09-28 2010-05-06 Bioriginal Food & Science Corp Fad4, fad5, fad5-2 e fad6, novos membros da família de dessaturases de ácidos gordos e susas utilizações
CN1259044C (zh) 2001-03-30 2006-06-14 日清奥利友集团株式会社 骨代谢改善剂
JP2003048831A (ja) * 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
AU778384B2 (en) * 2001-11-14 2004-12-02 Virtus Nutrition Llc Method for manufacturing fatty acid calcium salts from high glyceride content oils
DE60325590D1 (de) * 2002-06-19 2009-02-12 Dsm Ip Assets Bv Pasteurisationsverfahren für mikrobielle zellen und mikrobielles öl
PT1542670E (pt) * 2002-09-24 2013-07-11 Suntory Holdings Ltd Composição com efeitos na prevenção do declínio, melhoramento ou aumento de respostas normais de aptidões cognitivas de uma pessoa saudável
WO2004095940A1 (en) * 2003-04-25 2004-11-11 The University Of Newcastle Biomass containing animal feed
US8633247B2 (en) 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Method for decreasing cartilage damage in dogs
US8633246B2 (en) 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Omega-3 fatty acids for osteoarthritis
EP1765964A4 (en) 2004-04-30 2007-11-07 SYNTHESIS OF METALLIC SALTS OF MONOVALENT AND DIVALENT POLYUNSATURATED FATTY ACIDS
US8637495B2 (en) * 2004-07-01 2014-01-28 Nestec S.A. Osteoarthritis diet formulations
ES2253089B1 (es) * 2004-07-16 2007-08-16 Berthol Victor Laboratorios Ordesa, S.L. Complemento nutraceutico para la preparacion de leches infantiles.
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP2006083136A (ja) * 2004-09-17 2006-03-30 Suntory Ltd ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
EP1772146A1 (en) * 2005-10-03 2007-04-11 Neuropharma, S.A. Polyunsaturated fatty acids as bace inhibitors
EP3593797A1 (en) 2006-12-28 2020-01-15 Suntory Holdings Limited Nerve-regenerating agent
US20090202672A1 (en) * 2008-02-11 2009-08-13 Monsanto Company Aquaculture feed, products, and methods comprising beneficial fatty acids
CN101259101B (zh) * 2008-04-17 2010-06-02 湖北福星生物科技有限公司 微米级花生四烯酸和二十二碳六烯酸乳状液及其制备方法
GB2460056A (en) * 2008-05-14 2009-11-18 Arab Science & Technology Foun Compositions comprising omega-6 fatty acids for use in treating schistosomiasis
WO2011053870A1 (en) 2009-10-30 2011-05-05 Retrotope, Inc. Alleviating oxidative stress disorders with pufa derivatives
KR102111997B1 (ko) 2011-04-26 2020-05-18 레트로토프 인코포레이티드 Ｐｕｆａ와 관련된 신경퇴행성 질환 및 근육 질환
KR102020579B1 (ko) 2011-04-26 2019-09-10 레트로토프 인코포레이티드 에너지 프로세싱 손상 장애 및 미토콘드리아 결함
US10154978B2 (en) 2011-04-26 2018-12-18 Retrotope, Inc. Disorders implicating PUFA oxidation
WO2012148930A2 (en) * 2011-04-26 2012-11-01 Retrotope, Inc. Oxidative retinal diseases
EP2745706A1 (en) * 2012-12-24 2014-06-25 Abbott Laboratories, Inc. Methods for maintaining bone quality
EP2958982B1 (en) 2013-12-20 2019-10-02 Mara Renewables Corporation Methods of recovering oil from microorganisms
MA41611A (fr) * 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
JP7048976B2 (ja) 2015-11-23 2022-04-06 レトロトップ、 インコーポレイテッド １，４－ジエン系の部位特異的同位体標識
US10851395B2 (en) 2016-06-10 2020-12-01 MARA Renewables Corporation Method of making lipids with improved cold flow properties
EP4107163A4 (en) 2020-02-21 2024-06-19 Retrotope, Inc. PROCESS FOR ISOTOPIC MODIFICATION OF POLYUNSATURATED FATTY ACIDS AND THEIR DERIVATIVES
WO2024050589A1 (en) * 2022-09-07 2024-03-14 Nourish Ingredients Pty Ltd Compositions and methods for producing meat-like aromas

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8916734D0 (en) * 1989-07-21 1989-09-06 Efamol Holdings Pharmaceutical and dietary uses of fatty acids
PH11992043811B1 (en) 1991-01-24 2002-08-22 Martek Corp Arachidonic acid and methods for the production and use thereof
US5658767A (en) † 1991-01-24 1997-08-19 Martek Corporation Arachidonic acid and methods for the production and use thereof
ZA92452B (en) * 1991-01-24 1992-10-28 Martek Corp Microbial oil mixtures and uses thereof
JPH0692848A (ja) * 1992-09-11 1994-04-05 Sagami Chem Res Center 糖尿病治療用乳剤
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
JPH06271464A (ja) * 1993-03-19 1994-09-27 Tokiwa Yakuhin Kogyo Kk 消化器系障害の予防または治療用アラキドン酸含有組成物
CA2164291C (en) * 1993-06-09 2007-10-30 David John Kyle Methods and pharmaceutical compositions useful for treating neurological disorders
JPH07267856A (ja) * 1994-02-09 1995-10-17 Green Cross Corp:The 経口免疫抑制剤
GB9510636D0 (en) * 1995-05-25 1995-07-19 Scotia Holdings Plc Fatty acid treatment
EP0831805A1 (en) * 1995-06-07 1998-04-01 Martek Biosciences Corporation Methods for controlling highly unsaturated fatty acid content in various tissues
US6200624B1 (en) 1996-01-26 2001-03-13 Abbott Laboratories Enteral formula or nutritional supplement containing arachidonic and docosahexaenoic acids
DK2260716T3 (da) 1996-03-26 2014-05-12 Dsm Ip Assets Bv Sen tilsætning af PUFA ved fremstillingsproces for formulering til spædbørn
ES2177966T3 (es) 1996-03-26 2002-12-16 Dsm Nv Particulas de vehiculos solidos revestidas con acidos grasos poliinsaturados (pufa) para productos alimentarios.
CN1226923B (zh) 1996-03-28 2011-06-15 Dsmip资产有限公司 粒状微生物生物量的制备及其有价值的化合物的分离方法
CA2250581C (en) 1996-03-28 2008-08-12 Gist-Brocades B.V. Preparation of microbial polyunsaturated fatty acid containing oil from pasteurised biomass
FR2749133A1 (fr) * 1996-06-04 1997-12-05 Pierre Moreau Obtention d'oeufs specifiquement enrichis en acide cervonique (acide docosahexaenoique ou dha). applications alimentaires, therapeutiques et industrielles de ces oeufs et de leurs extraits lipidiques
JP3792309B2 (ja) * 1996-08-30 2006-07-05 サントリー株式会社 不飽和脂肪酸含有油脂の製造方法
JP4633204B2 (ja) * 1996-10-11 2011-02-16 サントリーホールディングス株式会社 アラキドン酸含有食用油脂およびそれを含有する食品

Also Published As

Publication number Publication date
EP2292223A1 (en) 2011-03-09
DE69935995T2 (de) 2008-01-10
DK1121115T3 (da) 2007-07-02
NZ511071A (en) 2004-01-30
AU2004224924B2 (en) 2008-02-28
US20070184090A1 (en) 2007-08-09
HK1042441A1 (zh) 2002-08-16
CA2355341A1 (en) 2000-04-20
JP2011098966A (ja) 2011-05-19
ES2284286T3 (es) 2007-11-01
AU1152000A (en) 2000-05-01
EP1121115A1 (en) 2001-08-08
WO2000021524A1 (en) 2000-04-20
DE69935995D1 (de) 2007-06-14
JP2002527387A (ja) 2002-08-27
CA2653503A1 (en) 2000-04-20
EP2308486A1 (en) 2011-04-13
US20090105342A1 (en) 2009-04-23
CN101283807A (zh) 2008-10-15
ATE361066T1 (de) 2007-05-15
EP1121115B2 (en) 2010-08-18
AU2004224924A1 (en) 2004-11-25
AU775421B2 (en) 2004-07-29
EP1121115B1 (en) 2007-05-02
CN1326344A (zh) 2001-12-12
ES2284286T5 (es) 2011-01-03
DE69935995T3 (de) 2011-02-10
EP1803451A1 (en) 2007-07-04
CA2355341C (en) 2009-04-14
CN102090636A (zh) 2011-06-15

Similar Documents

Publication Publication Date Title
DK1121115T3 (da) PUFA-tilskud
US5198468A (en) Essential fatty acid composition
EP0347056B1 (en) Essential fatty acid compositions
DK1041896T3 (da) Fedtblanding
TW200744463A (en) Nutritional supplement containing long-chain polyunsaturated fatty acids
CA2281706A1 (en) Methods and compositions for reducing the incidence of necrotizing enterocolitis
KR940018091A (ko) 불포화 지방산을 포함하는 처방
CA1310911C (en) Essential fatty acid compositions
SG143274A1 (en) Nutrition containing fat blend
PT1152755E (pt) Acidos gordos essenciais destinados a prevencao de acidentes cardio-vasculares
EP1211305A4 (en) FAT COMPOSITIONS
ES2149253T3 (es) Medicamentos a base de acido docosahexaenoico como antiagregantes plaquetarios y contra las carencias cerebrales en acidos grasos esenciales y procedimientos de preparacion.
DK1027831T3 (da) Stabiliseret fedtstofsammensætning, fremgangsmåde til fremstilling deraf og ernæringsprodukt indeholdende denne
CN1212867A (zh) 防治心脑血管疾病的组合物
Steffens et al. The importance of silver carp and bighead carp as dietetic foodstuffs for prophylaxis and therapy of cardiovascular diseases.
Sullivan et al. Distribution on n− 3 polyunsaturated fatty acids in different edible portions of the blue swimmer crab (Portunus pelagicus)
Suzuki et al. Effect of lard, palm and rapeseed oils life conservation in aged mice